Skip to main content

First Patient In (FPI): How to Reach This Critical Milestone Faster

Reaching first patient in is one of the most closely watched milestones in a clinical trial. It signals that months of planning, regulatory review, site activation, and recruitment strategy have come together. Yet for many sponsors and contract research organizations (CROs), FPI consistently arrives later than projected. 

According to McKinsey, 80 percent of trial sites experience delays due to enrollment issues. Additionally, Tufts Center for the Study of Drug Development (CSDD) data shows that 37 percent of sites enroll fewer participants than planned and 11 percent enroll no participants at all. These aren’t outliers. They reflect systemic challenges in how trials are planned, sites are selected, and start-up is managed. 

Understanding what drives delays and what accelerates FPI can meaningfully compress timelines and protect study outcomes. 

What Does ‘First Patient In’ Mean in a Clinical Trial? 

First patient in or FPI refers to the date on which the first participant reaches a study-defined enrollment milestone, typically consent, enrollment/randomization, or receipt of the first study intervention. It’s the transition point from study start-up to active execution. 

FPI is also a performance benchmark. Sponsors track time to ‘first patient in’ as a measure of how efficiently a trial moved through site activation, regulatory approvals, and early recruitment. A delayed FPI often signals upstream problems in contracting, feasibility, or site readiness. 

Why Is Time to ‘First Patient In’ So Difficult to Achieve on Schedule? 

According to WCG’s 2026 Clinical Research Site Challenges Report, more than half of sites surveyed spent at least three months on study start-up, and for 13%, the process extends beyond five months, leading to delayed enrollment.

Budgets development and negotiations were noted as the largest contributor to study start-up timelines by 56 percent of sites. Sponsor/CRO engagement (43 percent) and clinical trial agreement (CTA) negotiations (38 percent) followed as the second and third largest contributors. 

These challenges are all compounded by protocol complexity. Since 2015, Phase III trials have seen a 42 percent increase in required procedures and a 37 percent increase in the number of endpoints, according to the Tufts CSDD. These various factors add to complexity and mean longer site activation timelines and slower first enrollment. 

Five Ways to Accelerate Time to ‘First Patient In’ 

1. Prioritize Site Feasibility Early 
Matching the right sites to your protocol before start-up begins is critical. Delays often trace back to sites that lack the right participant population, infrastructure, or investigator experience. Using data-driven feasibility tools, such as WCG’s Trial IntelX™, powered by ClinSphere®, helps identify high-performing sites with documented success in similar protocols. 

2. Streamline Budget and Contract Negotiations 
Budget and contract negotiations are the single biggest driver of start-up delays. Sites that follow industry-leading negotiation best practices can reduce budget and contract timelines by up to 40 to 60 percent. Resolving these components early keeps the entire start-up sequence on track. 

3. Proper Preparation for IRB Review 
Incomplete or poorly prepared submissions cause avoidable delays in ethical review. Working with an experienced review partner, like WCG, whose full-board IRB review determinations are 40% faster than targeted turnaround times. 

4. Build a Strong Medicare Coverage Analysis (MCA) Foundation 
A high-quality MCA informs accurate budgeting, which in turn supports smoother budget negotiations and efficient CTMS builds. Each component depends on the quality of the one before it. Skipping or rushing the MCA creates delays that compound downstream. 

5. Launch Recruitment Strategy in Parallel with Start-Up 
Recruitment planning shouldn’t wait for site activation. Centralized outreach campaigns, participant-facing content, and site-level recruitment plans developed during start-up allow enrollment to begin the moment sites are activated. 

Frequently Asked Questions

FPI is the date the first eligible participant is enrolled and receives the investigational treatment in a clinical trial. It marks the official start of study execution and is used as a key benchmark for study start-up performance. 

Timelines vary depending on protocol complexity, therapeutic area, and site type. According to the 2026 Clinical Research Site Challenges Report, nearly 30 percent of sites said study start-up took three to four months. 

The most common causes include budget development and negotiation delays, sponsor engagement and responsiveness, contract negotiations, and overall complexity of trials. 

Choosing sites without the right participant population, investigator experience, or operational capacity leads to activation delays and low enrollment rates. Data-driven site identification significantly reduces this risk. 

Yes. Developing centralized recruitment campaigns, community outreach strategies, and site-level recruitment plans during the start-up phase allows enrollment to begin as soon as sites are ready, reducing time to ‘first patient in.’ 

How WCG Can Help You Reach FPI Faster 

WCG’s Study Start-Up Solutions address the core drivers of FPI delays, including coverage analysis, budget and contract negotiation, CTMS builds, and site enablement. Combined with centralized recruitment support and data-driven site selection, WCG gives sponsors and CROs the infrastructure to reach ‘first patient in’ on time.

Accelerate your start-up timelines and enroll patients sooner with WCG's Study Start-up solutions

Complete the form to schedule a consultation with WCG.